DiscoverPharmacy Podcast Network
Pharmacy Podcast Network

Pharmacy Podcast Network

Author: Pharmacy Podcast Network

Subscribed: 1,824Played: 81,621
Share

Description

Pharmacy Podcast Network (PPN) is the world’s largest network of podcasts dedicated to the pharmacy professional and industry insiders. Our content is about dynamic people in the pharmacy industry making a difference and delivering the best pharmacy care. We have over 40+ podcasts with thousands of interviews. 

Pharmacists are the cornerstone of healthcare, and the PPN reflects that. From Community, LTC, Specialty Pharmacy to Drug Development, Government policy and DigitalHealth, we cover it all. Partner with us to connect with thousands of daily listeners and find the right pharmacist across various specialties and topics, ensuring your products and services resonate where it matters most. We build strong audio brands through Pharmacists who see patients almost 9x more than primary care.



Join the home of the O.G. Pharmacy Podcast & discover our newest development: Evidence-based Podcasting, the first CME supplement in podcast form that's truly peer-reviewed. The future of podcasting education for Providers is "Evidence-based Podcasting" (TM) and we're building a peer-review board, reach out to us: Publisher @ Pharmacy Podcast dot com. 



PPN is a division of RxPR, LLC. Copyright 2026 

1771 Episodes
Reverse
This week on TWIRx, we head into NCPA 2026 with independent community pharmacy front and center — from artificial intelligence and consolidation to supply-chain economics and policy reform.   We start with the TWIRx Rumor Mill — Behind the Counter Intelligence, looking at three developing stories worth watching.   TWIRx RUMOR MILL — TOP 3   1. Another massive pharmacy transaction may be coming.   The owner of Walgreens Boots Alliance is reportedly nearing a deal to sell UK pharmacy giant Boots to the Weston family in a transaction valued at roughly $9 billion, including debt. The Weston interests already control Loblaw Companies and Shoppers Drug Mart in Canada. No final transaction has been announced, so this remains one to watch.   TWIRx Take: Pharmacy consolidation isn't slowing down. As major organizations continue reorganizing, buying, selling, and vertically integrating assets, what does that mean for independent pharmacy — and where does scale become too much scale?     2. Specialty pharmacy keeps getting bigger — and Cigna sees an enormous opportunity.   At its 2026 Investor Day, Cigna identified a specialty pharmacy and care-services market approaching $500 billion, with Accredo and its specialty operations positioned as major growth drivers.   TWIRx Take: Follow the money. Specialty drugs, rare disease, biologics, infusion and complex medication management continue to reshape pharmacy economics. The question for community pharmacy is: How much of this expanding market can independents capture?   3. AI is moving from pharmacy experiment to pharmacy infrastructure.   Just as NCPA prepares to make AI implementation one of the major topics at its 2026 Annual Convention, health-profession regulators are increasingly discussing governance and accountability surrounding AI. NCPA's programming includes real-world AI implementation and operational applications for community pharmacies.   TWIRx Take: The conversation is changing from "Should pharmacy use AI?" to "How do we use it responsibly, profitably and safely?"   And that takes us directly into our first featured conversation.   SEGMENT 1 John Boos, PharmD, MBA — HendrenAI AI Meets Independent Community Pharmacy   Sponsored by HendrenAI and Independent Pharmacy Cooperative   NCPA 2026 officially opens October 3 in Kansas City, with independent pharmacy owners and innovators gathering to focus on practical ways to increase efficiency, expand services and strengthen pharmacy profitability. AI implementation is specifically among this year's featured topics.   In Part One of our conversation with John Boos, PharmD, MBA of HendrenAI, we set the stage for NCPA 2026 and examine what artificial intelligence can realistically do for independent pharmacy.   This isn't AI replacing the pharmacist.   It's AI giving pharmacists and their teams additional capacity.   As margins tighten and workload continues to increase, the pharmacies that intelligently automate routine work may be able to redirect valuable human time toward the things pharmacists do best: patients, clinical care, relationships and growing the business.   SEGMENT 2 Yvonne Dominguez — Independent Pharmacy Cooperative IPC Acquires IntegralRx   Independent Pharmacy Cooperative recently announced its acquisition of IntegralRx, bringing together two organizations serving independent community pharmacies.   IntegralRx has supported thousands of pharmacies through purchasing opportunities, service and pharmacy relationships. IPC says the acquisition will expand access to products, services and resources designed to help pharmacy owners remain competitive and profitable.   We talk with Yvonne Dominguez about:   Why IPC made the acquisition What IntegralRx brings to the cooperative What changes — and what stays the same — for IntegralRx pharmacies How scale can strengthen independent pharmacy purchasing power Why independent pharmacies increasingly need collaboration without surrendering their independence   TWIRx Question: Can cooperatives create enough collective scale to give independent pharmacies some of the economic leverage enjoyed by vertically integrated competitors?   SEGMENT 3 David A. Hargraves — CEO, Pharma Logistics Jessica Daley — Industry Intelligence Pharmacy Supply Chain: Fighting for Every Dollar   Finally, we turn to an issue that doesn't always generate headlines but directly affects pharmacy profitability:   What happens to medication inventory after a pharmacy can no longer use it?   Pharmacies continue to face significant economic pressure, and many of the largest forces affecting reimbursement remain outside the direct control of the pharmacy owner.   But there are areas pharmacies — and policymakers — can change.   One is pharmaceutical return policy.   The Problem   Pharmacy economics are being squeezed from multiple directions.   Reimbursement pressure. Inventory expense. Expired medication. Operational costs. Supply-chain complexity.   When margins are razor thin, seemingly small inefficiencies become substantial.   The Opportunity   Medication return policies represent an area where pharmacies may have an opportunity to recover value that otherwise disappears from the business.   Virginia's regulations, for example, specifically address circumstances under which drugs can be returned within the supply chain while maintaining appropriate storage conditions, documentation and product integrity.   The Bigger Conversation   With David A. Hargraves, CEO of Pharma Logistics, and Jessica Daley of Industry Intelligence, we examine how smarter pharmaceutical returns and responsible policy reform could improve pharmacy economics.   Closing Thought   As we head into NCPA 2026, the independent pharmacy conversation isn't simply about surviving another difficult year.   It's about finding leverage.   Leverage through AI.   Leverage through cooperative scale.   Leverage through better supply-chain economics.   And leverage through policy change.   Independent pharmacy may not control every economic force affecting the profession — but this week's TWIRx demonstrates that there are still areas where pharmacy owners, innovators and advocates can take action.   We'll see you in Kansas City for NCPA 2026.
In this podcast episode, I interview Dr. Sarah Apple, a board-certified occupational therapist and the owner of Happy Pelvis Pelvic Floor Therapy in Cookeville, TN. Dr Apple talks about how she has dedicated her practice to helping women better understand and care for their pelvic health. In addition, we discuss how pelvic health relates to sex therapy. Dr Sarah Apple's Bio: Dr. Sarah Apple is a board-certified occupational therapist and the owner of Happy Pelvis Pelvic Floor Therapy, a local practice in Cookeville, TN dedicated to helping women better understand and care for their pelvic health. She specializes in pelvic floor therapy through pregnancy, postpartum, and beyond, with a passion for helping women recognize that common symptoms aren’t always something they simply have to live with. Through Happy Pelvis, Sarah strives to educate, empower, and help women feel confident in their bodies. Practice Website: https://www.happypelvistherapy.com/ Facebook Link: https://www.facebook.com/profile.php?id=61565217837049 LinkedIN: https://www.linkedin.com/in/sarah-apple-otd-otr-l-58817a236/
Welcome everyone to the Bottom Line Rewind, your monthly recap of the Bottom Line Pharmacy Podcast. This month, we feature interviews on topics about operating an Infusion pharmacy in 2026, distributor cutoffs, peptides, and personal guarantee insurance. Click below to check out the full episodes: Episode 1: Infusion Pharmacy Ownership in 2026: https://youtu.be/rdMKsMjN8Zs?si=jqZq-MXU7IVk3KmB Episode 2: Distributor Injunctive Relief: https://youtu.be/hAAo6AY-Ai0?si=2nbb6GVyaN9qr44A Episode 3: Peptides, Nexus Issues, and Tradeshow Takeaways: https://youtu.be/8_clXDyhVbM?si=2s-6je4YAG26889m Episode 4: Personal Guarantee Insurance 101: https://youtu.be/4v3cRtMvfIM?si=k0h36O_CIc7-IaCC Episode 5: Financing a Pharmacy Acquisition: https://youtu.be/CYxfBISoBco?si=kzEzUdmUh6YHXRvz
In this episode, Sheila Arquette, President & CEO of NASP, speaks with Rita Jew, PharmD, MBA, President of the Institute for Safe Medication Practices (ISMP), about what it takes to keep specialty medication use safe. They discuss the distinct risks of specialty medications and detail ISMP's mission to prevent medication errors, providing drug-specific risk assessments, resources, and interactive tools that help pharmacies uncover gaps between policy and practice.
Thomas E. Hanzel joins host Todd Eury to discuss how AI, automation, data access, and emerging at-home care models can help long-term care pharmacies improve efficiency, expand patient care, and diversify revenue. Host: Todd Eury Guest: Thomas E. Hanzel, PharmD, MBA
loading
Comments